6 Results for "

YAP-TEAD binding

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "YAP-TEAD binding" in MCE Product Catalog:

26
26 Publications Verification
Cat. No.: HY-B0990
CAS No.: 1393-48-2
Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P2244A
CAS No.: 1659305-79-9
Target:  

YAP

Research Areas:  

Cancer

YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC50=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (Kd=15 nM) than YAP (50-171) (Kd= 40 nM) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P2244
CAS No.: 1659305-78-8
Target:  

YAP

Research Areas:  

Cancer

YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC50=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (Kd=15 nM) than YAP (50-171) (Kd=40 nM) .
loading...
    loading...
Cat. No.: HY-161443
Target:  

YAP

Research Areas:  

Cancer

TEAD-IN-9 (compound 17) is a TEAD1 inhibitor with an IC50 of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .
loading...
    loading...
Cat. No.: HY-179706
CAS No.: 2576427-49-9
Target:  

YAP

Research Areas:  

Cancer

VS3 is a YAP-TEAD interaction inhibitor. VS3 directly disrupts the interaction between YAP-TEAD by binding to TEAD4 Interface 3 (Kd = 6 μM) on the surface. VS3 exhibits anti-proliferative activity against HT29, HCT116, and A2780. VS3 can be used for research on colorectal adenocarcinoma and ovarian cancer .
loading...
    loading...
Cat. No.: HY-189200
CAS No.: 3006101-94-3
Target:  

YAP Hippo (MST)

Research Areas:  

Cancer

AZ'4331 is an orally active pan-TEAD family inhibitor, with an IC50 of 0.381 μM against TEAD1, 0.020 μM against TEAD2, 0.014 μM against TEAD3, and 0.031 μM against TEAD4. AZ'4331 slows cell cycle progression. AZ'4331 exerts effects in cancer xenograft models with dysregulated Hippo pathway. AZ'4331 can be used to study cancers with altered Hippo pathways, including mesothelioma, head and neck squamous cell carcinoma, and EGFR-mutant non-small cell lung cancer .
loading...
    loading...